Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2

BACKGROUND: Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-ly...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Lu, Xiaomin, Devidas, Meenakshi, Reid, Joel M., Goldenberg, David M., Wegener, William A., Zeng, Hui, Whitlock, James A., Adamson, Peter C., Hunger, Stephen P., Carroll, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701208/
https://ncbi.nlm.nih.gov/pubmed/25732247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25454
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados